Carcinosarcoma

Subscribe to Selected New Research on Carcinosarcoma

770 relevant articles (33 outcomes, 74 trials/studies) found for this Disease

Description: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)

Also Known As:

Carcinosarcomas

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Histologic Type: 1

Complex and Mixed Neoplasms

Carcinosarcoma: 770

Walker Carcinoma 256: 94

Connective and Soft Tissue Neoplasms

Sarcoma: 10707

Carcinosarcoma: 770

Walker Carcinoma 256: 94

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Ascites
4.	Lewis Lung Carcinoma
5.	Sarcoma (Soft Tissue Sarcoma)

Experts

1.	Kawarabayashi, Tatsuhiko: 4 articles (03/2005 - 04/2003)
2.	Emoto, Makoto: 4 articles (03/2005 - 04/2003)
3.	Madeja, Zbigniew: 3 articles (01/2008 - 01/2002)
4.	Sroka, Jolanta: 3 articles (01/2008 - 01/2002)
5.	Gynecologic Oncology Group: 3 articles (02/2007 - 05/2004)
6.	Niggli, Verena: 2 articles (04/2007 - 08/2005)
7.	Gutjahr, Marc C: 2 articles (04/2007 - 08/2005)
8.	Rossy, Jérémie: 2 articles (04/2007 - 08/2005)
9.	Homesley, Howard D: 2 articles (02/2007 - 05/2004)
10.	Vergote, I: 2 articles (09/2005 - 03/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Carcinosarcoma:

1.	Cisplatin (Platino)FDA LinkGeneric 04/01/1997 - "Furthermore, the addition of BP to cisplatin had no apparent effect on the efficacy of cisplatin against Walker 256 carcinosarcoma cells in rats. " 05/01/2004 - "CONCLUSIONS: These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. " 01/01/2001 - "However, carcinosarcomas respond better to cisplatin-based regimens. " 08/01/1992 - "Cisplatin in gynecologic carcinosarcoma." 11/01/1989 - "Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma." Order ALL the reference details at left...
2.	Ifosfamide FDA LinkGeneric 01/01/1976 - "Pretreatment by repeated small doses of ifosfamide resulted in resistance of DS-carcinosarcoma against curative action of subsequent high single doses of this drug." 09/01/1975 - "Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. " 01/01/1976 - "Therefore, using massive single doses of ifosfamide, rats could be cured of DS-carcinosarcoma in higher percentage than by an analogous treatment with cyclophosphamide. " 02/10/2007 - "PURPOSE: To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity. " 11/01/2000 - "CONCLUSION: The addition of cisplatin to ifosfamide appears to offer a small improvement in progression-free survival over ifosfamide alone in the management of advanced carcinosarcoma of the uterus; the added toxicity may not justify the use of this combination." Order ALL the reference details at left...
3.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/01/2004 - "However, only 5 cases of carcinosarcoma of the urinary bladder following cyclophosphamide therapy have been reported. " 01/01/2004 - "Carcinosarcoma of the urinary bladder following cyclophosphamide therapy: evidence for monoclonal origin and chromosome 9p allelic loss." 10/01/1991 - "Carcinosarcoma of bladder following long-term cyclophosphamide therapy." 11/29/1977 - "The resistance to cyclophosphamide which was detected in animal experiments with Walker carcinosarcoma can therefore also be observed using the in vitro short term test." 11/29/1977 - "Treatment of the solid Walker carcinosarcoma of the rat for a period of one year with cyclophosphamide (40 mg/kg at each passage; tumours were transplanted weekly) resulted in the formation of a cyclophosphamide-resistant tumour cell line. " Order ALL the reference details at left...
4.	Paclitaxel (Taxol)FDA LinkGeneric 11/01/2001 - "OBJECTIVE: The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. " 11/01/2001 - "Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study." 11/01/2001 - "CONCLUSIONS: Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. " 02/10/2007 - "PURPOSE: To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity. " 02/10/2007 - "Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study." Order ALL the reference details at left...
5.	Carboplatin (JM8)FDA LinkGeneric 08/01/1995 - "The remission has lasted more than 4 months, which has suggested the efficacy of CBDCA for uterine carcinosarcoma." 08/01/1995 - "[A case of remission of recurrent carcinosarcoma of the uterus with massive ascites by carboplatin]" 08/01/1995 - "A case of remission of recurrent carcinosarcoma of the uterus with massive ascites by chemotherapy using carboplatin (CBDCA) is reported. " 09/01/2004 - "Six patients pathologically diagnosed with uterine carcinosarcoma were treated with paclitaxel (175 mg/m(2) given intravenously over 3 h) and carboplatin (dosed at AUC 6) every 3 weeks at our center between 1997 and 2003. " 09/01/2004 - "Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus." Order ALL the reference details at left...
6.	O-(chloroacetylcarbamoyl)fumagillol (TNP 470)IBA 01/01/2000 - "CONCLUSIONS: Our in vitro findings suggest that this angiogenesis inhibitor, TNP-470, might be a novel therapeutic agent for uterine carcinosarcoma. " 01/08/2004 - "Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470." 04/01/2003 - "We speculate that TNP-470 may be a useful agent for adjuvant therapy in patients with advanced or recurrent uterine carcinosarcomas. " 04/01/2003 - "CONCLUSION: These results suggest that TNP-470 may inhibit the growth of human uterine carcinosarcoma in vivo. " 04/01/2003 - "METHODS: The growth-inhibitory and anti-angiogenic effects of TNP-470 were examined after inoculating a human uterine carcinosarcoma cell line, FU-MMT-1, in nude mice. " Order ALL the reference details at left...
7.	Methionine (L-Methionine)FDA Link 04/01/1990 - "L-Methionine was also effective in reducing the renal toxicity induced by CDDP when given orally 20 min before the iv administration of 7.5 mg CDDP/kg. L-Methionine did not compromise the efficacy of CDDP when the antitumor activity of the combination of L-methionine and CDDP was measured against the Walker 256 carcinosarcoma in the rat. " 08/01/1988 - "To evaluate the feasibility of using either L-[1-11C]-methionine or L-[methyl-11C]methionine for measuring protein synthesis rates by positron emission tomography (PET) in normal and neoplastic tissues, distribution and metabolic studies with 14C- and 11C-labeled methionines were carried out in rats bearing Walker 256 carcinosarcoma. " 03/01/1983 - "These differences illustrate changes in tissue folates with the proliferation rate of the tissue and suggest an explanation for the methionine auxotrophy of Walker 256 carcinosarcoma cells." 03/01/1980 - "Methionine metabolism in Walker carcinosarcoma in vitro." 03/15/1990 - "L-Methionine administered simultaneously with cis-platinum (CDDP) iv results in a significant reduction of the nephrotoxicity normally associated with CDDP without any apparent effect on the antineoplastic activity for rats bearing the Walker 256 carcinosarcoma. " Order ALL the reference details at left...
8.	Doxorubicin (Adriamycin)FDA LinkGeneric 07/01/1993 - "Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery." 01/01/1988 - "To test this hypothesis, we examined the effectiveness of HpD-PT in the Walker 256 carcinosarcoma with and without Adriamycin. " 05/01/2001 - "Doxorubicin (DXR) was bound to these carriers via a peptide spacer, GlyGlyPheGly (GGFG), to give carrier-GGFG-DXR conjugates (DXR content: 4.2-7.0 (w/w)%), and the antitumor effects of these conjugates were tested with Walker 256 carcinosarcoma-bearing rats by monitoring the tumor weights after a single intravenous injection. " 09/01/2006 - "CONCLUSION: Cisplatin and doxorubicin may be effective in pulmonary carcinosarcoma. " 05/01/2000 - "Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR. " Order ALL the reference details at left...
9.	NimustineIBA 01/01/1994 - "Clearance of ACNU from the CSF space and brain was relatively fast and the half time of ACNU concentration at the cortical or ventricular surface was 10 min. In rats with leptomeningeal tumor induced by intracisternal inoculation of Walker 256 carcinosarcoma cells, the distribution pattern of ACNU after intracisternal administration was essentially the same as in normal rats until the tumor had grown in the subarachnoid space to form more than 10 or 20 layers of tumor cells. " 03/01/1987 - "In the previous reports, we demonstrated that intracisternal ACNU is effective in prolonging the survival time of rats with meningeal carcinomatosis induced by intracisternal inoculation of Walker 256 carcinosarcoma cells, and systemic and local toxicity can be avoided by adjusting the drug dose. " 10/01/1997 - "Therapeutic effect of intrathecal ACNU (IT ACNU) against meningeal carcinomatosis model was evaluated in rats induced by intracisternal inoculation of Walker 256 carcinosarcoma cells. " 11/01/1988 - "Systemic and local toxicity was not observed in the rat given less than 1.5 mg/kg. Therapeutic effect of intrathecal ACNU against leptomeningeal tumors was evaluated in the rat with meningeal carcinomatosis induced by intracisternal inoculation of Walker 256 carcinosarcoma cells. " 11/01/1986 - "These changes were not observed in the animal given ACNU less than 1.5 mg/kg. Therapeutic effect of intrathecal ACNU against the leptomeningeal tumor was studied in rats with meningeal carcinomatosis which was induced by intracisternal inoculation of 1 X 10(4) cells of Walker 256 carcinosarcoma. " Order ALL the reference details at left...
10.	Carbon MonoxideIBA 02/01/2001 - "Co-expression of TN-C and Vim was detected in the carcinosarcoma cell line HS 578T, SK-BR-3 (B), fibroblast-like MDA-MB-231 cells, and the myoepithelial cell line HBL 100. " 06/15/1989 - "When co-inoculated with the tumorigenic fibroblasts in syngeneic hosts, however, the subcloned epithelial cells again formed carcinosarcomas. " 06/15/1989 - "Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals." 01/15/1979 - "Neutron activation analysis of peripheral lymphocytes from healthy and Walker 256 carcinosarcoma-bearing rats resulted in the quantitative determination of Co, Cu, K, Mn, Rb, Se and Zn, and a qualitative determination of Au and Sb. " 04/01/2002 - "Co-existent carcinosarcoma and adenoid basal carcinoma of the uterine cervix and correlation with human papillomavirus infection." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2006 - "CONCLUSION: Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy seems to be an effective treatment for ovarian carcinosarcoma with peritoneal spread. " 01/01/2008 - "CONCLUSIONS: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma." 05/01/1991 - "MAID chemotherapy may be useful in the treatment of carcinosarcoma of the ovary." 02/01/2008 - "Some studies have shown improved survival of patients of carcinosarcoma of the uterine corpus whose treatment included postoperative radiation and chemotherapy. " 01/01/2006 - "Further studies are required to define the value of intraperitoneal chemotherapy in ovarian carcinosarcoma." Order ALL the reference details at left...
2.	Combination Drug Therapy (Combination Chemotherapy) 05/01/2009 - "Areas of focus included the feasibility of laparoscopic staging for endometrial cancer, the adjuvant management of locally advanced endometrial cancer, whole abdominal irradiation in maximally resected advanced endometrial carcinoma, and combination chemotherapy regimens for stage I and II carcinosarcoma after primary surgery and for advanced or recurrent carcinosarcoma. " 12/01/2008 - "Areas of focus included the feasibility of laparoscopic staging for endometrial cancer, the adjuvant management of locally advanced endometrial cancer, whole abdominal irradiation in maximally resected advanced endometrial carcinoma, and combination chemotherapy regimens for stage I and II carcinosarcoma after primary surgery and for advanced or recurrent carcinosarcoma. " 09/01/2004 - "OBJECTIVE: The purpose of the study was to evaluate the efficacy of combination chemotherapy with paclitaxel and carboplatin in patients with advanced or recurrent carcinosarcoma of the uterus. " 09/01/2008 - "Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution." Order ALL the reference details at left...
3.	Lymph Node Excision (Lymph Node Dissection) 10/01/2008 - "CONCLUSIONS: Lymphadenectomy is significantly associated with improved overall survival in patients with Stage I-III uterine carcinosarcoma compared to no lymphadenectomy. " 10/01/2008 - "Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis." 01/01/2006 - "In carcinosarcoma, significant differences were observed with age (p = 0.0388), stage (p < 0.01) and surgical procedure (with or without pelvic lymphadenectomy, p = 0.0316). " 02/01/2003 - "Omentectomy and lymphadenectomy should be performed in carcinosarcoma. " 01/15/2000 - "It is also recommended that an axillary lymph node dissection is not indicated, with the possible exception of patients with carcinosarcoma." Order ALL the reference details at left...
4.	Cystectomy 03/01/1996 - "Vesical carcinosarcoma is a very poor prognosis, infrequent tumour normally presenting with haematuria and for which the only treatment available is radical cystectomy. " 01/01/1993 - "Therefore, radical cystectomy appears to be the treatment of choice for both superficial and invasive carcinosarcoma of the urinary bladder." 02/01/2000 - "Carcinosarcoma of the urinary bladder is a uncommon tumor with characteristic histopathologic and immunohistochemical findings; his histogenesis have still not been clear; the prognosis seems to be improved by radical cystectomy and adjuvants therapies. " 06/01/2002 - "A 78-year-old woman with carcinosarcoma underwent total cystectomy, but she died from increasing multiple lung metastases 4 months after surgery. " 01/01/1993 - "Urethral carcinosarcoma following total cystectomy for bladder carcinoma." Order ALL the reference details at left...
5.	Heterologous Transplantation (Xenotransplantation) 06/01/2007 - "carcinosarcoma xenografts led to large areas of tumor cell necrosis and tumor disappearance in all treated animals. " 07/01/2006 - "EXPERIMENTAL DESIGN: Using nonobese diabetic/severe combined immunodeficiency mice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma. " 04/01/2003 - "Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice." 01/01/1991 - "The compound exhibited significant effects against various tumors such as P388 and L1210 leukemias; M5076 reticulum-cell sarcoma; colon 38 carcinoma; human xenografts MX-1, LX-1, GA-1, and Co-1; Lewis lung carcinoma; sarcoma 180; and Walker 256 carcinosarcoma and was especially effective against solid tumors. " 11/14/2005 - "We have examined the effect of the modified guanine base, O(6)-(4-bromothenyl)guanine (PaTrin-2, Patrin, Lomeguatrib) on MGMT activity and cell or xenograft tumour growth inhibition by temozolomide in the human breast carcinosarcoma cell line, MCF-7. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Carcinosarcoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 33 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>